APOE and atherosclerosis: Pre-clinical studies have shown that cyclodextrin can promote atherosclerosis regression in ApoE–/– mice by reprogramming macrophages (i.e., increased oxysterol production and consequent LXR-mediated increase of cholesterol efflux) (Zimmer et al., 2016).